Alnylam jumps as Q1 profit and record $1.17B revenue top expectations
ALNY•Alnylam shares rose after the company reported first-quarter 2026 results that beat expectations, including $206 million in net income and $1.17 billion in revenue. Investors focused on record product revenue above $1 billion, driven primarily by AMVUTTRA momentum.
1. What’s driving ALNY today
Alnylam Pharmaceuticals is moving higher today after reporting a stronger-than-expected first quarter (ended March 31, 2026), flipping to a $206 million profit ($1.51 per share) and delivering $1.17 billion in revenue, both ahead of consensus expectations. The report also highlighted a milestone: quarterly net product revenues surpassed $1 billion for the first time, reinforcing confidence in the company’s commercial trajectory. (wtop.com)
2. Key numbers investors are reacting to
The quarter featured $1.036 billion in global net product revenue, with growth driven primarily by AMVUTTRA and broader TTR-franchise strength, while total revenue reached $1.167 billion. The earnings beat was notable as adjusted EPS was reported at $1.99 versus expectations around the mid-$1 range, signaling improving operating leverage as revenues scale. (stocktitan.net)
3. What to watch next
After a sharp year-to-date pullback before today’s move, the market is likely to scrutinize management’s full-year outlook, the durability of AMVUTTRA demand in ATTR-CM, and whether the company can sustain profitability as it funds pipeline expansion. Any commentary on pricing dynamics, payer access, and upcoming clinical/regulatory milestones will be key to whether the post-earnings rally holds. (wtop.com)
